Research Reference
Thymosin Alpha-1
Immune-modulating peptide studied for viral infections and immunity
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Thymosin Alpha-1 is an immune-modulating peptide studied for viral infections and immune support. It is not FDA approved in the US.
Dosing Reference
Reconstitution
Add 1 mL bacteriostatic water to the 5 mg vial. Resulting concentration: 5 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 1.5 mg | 30 units | 0.3 mL | SubQ, twice weeklyStudied immune-support protocol |
| 1.6 mg | 32 units | 0.32 mL | SubQ, twice weeklyCommon community protocol |
| 5 mg | 100 units | 1 mL | SubQ, daily (acute)Higher acute protocol (studied) |
| 900 mcg | 18 units | 0.18 mL | SubQ, dailyChronic hepatitis B studied dose |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
Thymosin Alpha-1 (Tα1) is supplied as a lyophilized powder in 5 mg or 10 mg vials in compounded research-peptide form. It is not FDA-approved in the United States, though an approved formulation (Zadaxin) exists in some other countries.
For a 5 mg vial reconstituted with 1 mL of bacteriostatic water, the resulting concentration is 5 mg/mL; a 1.5 mg dose draws to 30 units (0.3 mL) on a U-100 insulin syringe. For a 10 mg vial reconstituted with 2 mL, the concentration is 5 mg/mL; a 1.5 mg dose draws to 30 units (0.3 mL). Gently swirl — do not shake — to mix. Store reconstituted vials refrigerated at 2–8°C and use within the period specified by the compounding source.
Cycling Protocol
Studied protocols describe thymosin alpha-1 administered twice weekly for an initial course of 6–12 months in chronic hepatitis B and C, and shorter courses (days to weeks) in acute viral and critical-illness contexts.
Community immune-support protocols commonly describe 1.5 mg subcutaneously twice weekly for 4–8 weeks, followed by a maintenance or off period. No standardized cycle length is established in the US, where the compound is not FDA-approved; durations in published studies vary by indication.
Routes of Administration
Subcutaneous injection (most common): Administered into the abdomen or thigh with a 29–31 gauge insulin syringe. This is the route used in the published clinical studies.
No oral, intranasal, or intravenous human route is established; thymosin alpha-1 is not orally bioavailable as a peptide.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | Immune Support | Thymosin Alpha-1 + Vitamin D / Zinc | Foundational immune support | | Viral Protocol | Thymosin Alpha-1 + interferon (clinical) | Studied combination in hepatitis protocols | | Recovery Stack | Thymosin Alpha-1 + BPC-157 | Immune + tissue repair (community) |
The combination with interferon is described in the clinical hepatitis literature under medical supervision. Community stacks are unvalidated extrapolation. Thymosin alpha-1 is not FDA-approved in the US.
Side Effects & Safety
- Injection-site reactions — redness or mild pain, the most commonly reported effect
- Fatigue or malaise — occasionally reported
- Low-grade fever — rarely, particularly with higher doses
- Allergic/hypersensitivity reactions — rare
- Generally well-tolerated in published clinical studies at studied doses
Thymosin alpha-1 is not FDA-approved in the United States. An approved formulation (Zadaxin) is available in some countries for specific viral indications. Compounded research-peptide forms are not FDA-approved.
Research Basis
Thymosin Alpha-1 is a 28-amino-acid peptide originally isolated from thymus extract, now produced synthetically.
Mechanism: Modulates T-cell maturation and immune function, enhancing cell-mediated immunity; studied for its effects on dendritic cell activity and cytokine balance.
Clinical evidence: Studied in chronic hepatitis B and C (often in combination with interferon), in certain cancers as an immune adjuvant, and in critical illness / sepsis contexts. An approved formulation exists in some countries outside the US.
Not FDA-approved in the US: Despite a body of published research, thymosin alpha-1 is not approved by the FDA for any indication in the United States. Compounded research-peptide forms are sold for research purposes only.